• News
  • BioTech

First patient treated in Genelux's Phase 1 trial

San Diego-based Genelux Corp. on Wednesday announced that researchers at Memorial Sloan Kettering Cancer Center (MSKCC) in New York treated the first patient in a Phase 1 clinical trial of GL-ONC1 in people with malignant pleural effusion, a complication that occurs in about 30 percent of lung cancers.

To continue reading, subscribe now
log in to your account
User Response
0 UserComments
Subscribe Today!